Lucid Diagnostics Inc. (LUCD) Market Cap
Lucid Diagnostics Inc. has a market capitalization of $134M.
Financials based on reported quarter end 2025-12-31
Price: $1.31
▲ 0.03 (2.34%)
Market Cap: 134.02M
NASDAQ · time unavailable
CEO: Lishan Aklog
Sector: Healthcare
Industry: Medical - Devices
IPO Date: 2021-10-14
Website: https://www.luciddx.com
Lucid Diagnostics Inc. (LUCD) - Company Information
Market Cap: 134.02M · Sector: Healthcare
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Analyst Sentiment
Based on 5 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 3 sources)
Consensus Price Target
Low
$2
Median
$3
High
$3
Average
$3
Potential Upside: 90.8%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"Lucid’s latest quarter (ending 2025-12-31) reported revenue of about $4.70B, but profitability was weak: net income was -$70.5B and EPS was $0.0058. Net margin was deeply negative, indicating substantial losses relative to sales. Cash flow was also materially strained: operating cash flow was -$23.5B and free cash flow was -$23.5B (with capital expenditure reported as $0 for the period). No dividends were paid. On the balance sheet, total assets were ~$40.4B versus ~$29.5B of total liabilities, leaving equity of ~$10.9B. Net debt was -$8.9B, which suggests the company was a net cash position overall—potentially offering resilience, but the large negative operating cash flow implies cash burn risk if profitability does not improve. Valuation context is limited by missing market-cap and key multiples, but the stock price was $1.15 with a -25.81% 1-year change. Analyst consensus price target is $2.50 (range $2.00–$3.00), implying expectations for improvement from current levels. Overall, shareholder returns have been pressured by negative price momentum, and cash-flow losses remain the central concern."
Revenue Growth
Revenue level was $4.70B, but the data provided does not include YoY/segment growth rates, limiting visibility into demand trends.
Profitability
Net income was -$70.5B with EPS of $0.0058, indicating very poor profitability and large negative net margin.
Cash Flow Quality
Operating cash flow and free cash flow were both -$23.5B. No dividends or buybacks were reported, and cash generation remains negative.
Leverage & Balance Sheet
Net debt was -$8.9B (net cash), with equity of ~$10.9B. While leverage appears manageable, ongoing operating losses could erode liquidity.
Shareholder Returns
Stock price fell -25.81% over 1 year. With $0 dividends and no buyback data provided, total shareholder return has likely been driven primarily by price performance, which is weak.
Analyst Sentiment & Valuation
Analyst consensus target of $2.50 vs. a $1.15 share price suggests upside expectations, but core valuation multiples are not available in the dataset.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management sounded upbeat on momentum—Q4 EsoGuard volume reached 3,664 tests (above the 2,500–3,000 target) and the VA milestone (FSS at the $938 Medicare-aligned rate) was framed as a major pathway to scale. The real-world dataset (~12,000 patients) strengthens the clinical case and supports faster procedures (<2 minutes; 95% success) versus legacy devices. However, the Q&A pressure point is reimbursement timing and revenue recognition mechanics: Medicare coverage is still pending due to “logistical delays,” and the draft/final LCD process (including a 45-day comment period) is what ultimately unlocks retroactive Medicare payments (back one year). Financially, Q4 recognized revenue was only ~$1.5M on ~$9.0M billable amounts (~17%), driven by ASC 606 variable consideration and pending adjudications (24% pending). Denials cluster around medical necessity, prior authorization, and missing records—so demand progress doesn’t yet fully convert to cash.
Growth Catalysts
- EsoGuard test volume 3,664 in Q4 2025 (vs target 2,500–3,000; +29% vs 2025 baseline)
- Sequential volume +~800 tests QoQ (question addressed: may become a new run rate, though not attributable directly to VA in the quarter)
- Real-world study (peer-review pending) in ~12,000 HET BRICK patients: EsoCheck cell collection technical success rate 95% and 95% of procedures completed in <2 minutes
- VA reimbursement pathway established via VA Federal Supply Schedule (FSS) priced at Medicare-aligned rate $938
Business Development
- Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard issued under VA Federal Supply Schedule (FSS) with pricing aligned to Medicare at $938
- UnitedHealthcare: de facto coverage signal via EGD guidelines—EsoGuard included as an appropriate indicator for coverage; company initiated UnitedHealthcare credentialing and plans contracting once credentialing threshold is met
- Cigna and potentially Anthem referenced as payers with similar (more complicated) contracting pathways
- Blue Cross Blue Shield Association (BCBSA) engagement referenced for future regional policy updates
- Integrated delivery networks (IDNs): engagement with a large West Coast network; expectation of near-term positive news
Financial Highlights
- Revenue: $1.50M in Q4 2025 (+24% vs 2025; based on >$9.0M billable value from >3,600 tests)
- Recognized revenue accounting: Q4 recognized revenue was ~17% of billable pro forma revenue ($1.5M recognized vs ~$9.0M billable); driven by ASC 606 variable consideration (collection probability) during reimbursement transition
- Claims adjudication (Q4): 76% adjudicated, 24% pending; of adjudicated, ~50% resulted in an allowable amount with average reimbursement of $16.23/test (near Medicare rate)
- Denied claims buckets (Q4): (1) medically not necessary / deemed not medically necessary, (2) requires prior authorization, (3) additional medical records
- Medicare impact stated: pending Medicare draft LCD affects 40%–50% of addressable patient population; also revenue recognition for Medicare tests with service dates within 12 months of final policy once paid after policy issuance
- Cash interest/debt note: 2024 refinancing into $22.0M five-year interest-only note at 12%
Capital Funding
- Cash at Dec 31, 2025: $34.7M
- Average burn rate (2025, incl. cash interest): $11.1M per quarter (Q4 higher due to ~$0.5M investments in sales/market access staffing and settlement of annual compensation obligations)
- Convertible notes fair value at year-end: $24.0M (mark-to-market quarterly adjustment $1.7M); no buyback disclosed
- Share count: ~177M shares outstanding (incl. unvested RSAs and Series B conversion) stated; Series B-1 converts May 6 (with dividends) adding ~16.8M common shares subject to a 4.99% ownership blocker
Strategy & Ops
- Resource reallocation: commercial team shifted incentives from event-based testing (fire departments, etc.) toward Medicare-focused physician/practice/health system engagements
- VA execution model: after FSS inclusion, coordinate cell collection at VA sites; engage clinical champions and execute PO issuance; appointed senior leader as National Director for the VA to convert engagements into contracts/revenue
- Satellite Lucid Test Center (SLTC) model described: co-locate nurses at physician practices on scheduled days; example cited of one clinician testing 30 patients in a day, largely Medicare patients
- EHR integration progression: using cost-effective systems now to support ordering and results delivery; plan to pursue direct Epic integration (Epicor) more aggressively later in 2026 when volume/integration maturity justifies spend
Market Outlook
- Medicare: awaiting publication of a draft LCD for EsoGuard; management says it is close
- Post-draft steps: mandatory 45-day comment period; final LCD and official notice/registry after comment period
- Retroactive payment timing: once final LCD/official notice is complete, company eligible for Medicare payments back to one year on claims
- Company expects volume/ramp from VA and Medicare efforts over coming weeks/quarters; analyst asked if 2,500–3,000 run-rate persists—management suggested it may become a new run rate but clarified VA not the driver of the Q4 sequential +800 increase
Risks & Headwinds
- Medicare reimbursement delay remains a central constraint: logistical delays for draft/final LCD; until finalized, variable consideration limits revenue recognition despite test activity
- Revenue recognition hurdle: insufficient predictive data to recognize revenue at report-delivery point (ASC 606); majority of claims recognized when collected
- Addressable patient exposure: pending Medicare coverage impacts 40%–50% of population; hence timing uncertainty materially affects near-term financials
- Commercial payer denial drivers (Q4): medically not necessary determinations, prior authorization requirements, and requests for additional medical records
- Cash burn / operating expense pressure: burn rate $11.1M/quarter; company emphasized not increasing resources and reallocating rather than expanding OpEx
Sentiment: CAUTIOUS
Note: This summary was synthesized by AI from the LUCD Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.